bioactive factors, produced by m2 macrophage
Biologicalexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02957123)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Attention Deficit Disorder with Hyperactivity · Phase 1/Phase 2
- Autism Spectrum Disorder · Phase 1/Phase 2
- Brain Ischemia · Phase 1/Phase 2
- Chronic Traumatic Encephalopathy · Phase 1/Phase 2
- Growth and Development · Phase 1/Phase 2
- Language Development Disorders · Phase 1/Phase 2
- Neurocognitive Disorders · Phase 1/Phase 2
- Speech Disorders · Phase 1/Phase 2
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bioactive factors, produced by m2 macrophage
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04689282 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2020 | Russian Academy of Medical Sciences |
| NCT02957123 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2016 | Russian Academy of Medical Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Russian Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 1 | 2016 |
1 organizations
Page 1 / 1